REVIEW ARTICLE
Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview
Anna Capasso*
Article Information
Identifiers and Pagination:
Year: 2017Volume: 11
First Page: 61
Last Page: 73
Publisher ID: TONEUJ-11-61
DOI: 10.2174/1874205X01711010061
Article History:
Received Date: 1/08/2017Revision Received Date: 2/11/2017
Acceptance Date: 20/11/2017
Electronic publication date: 18/12/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Objective:
Cannabinoid-based medications provide not only relief for specific symptoms, but also arrest or delay of disease progression in patients with pain, multiple sclerosis, and other conditions. Although they also seem to hold potential as anticonvulsant agents, evidence of their efficacy in epilepsy is supported by several evidences.
Method:
The data reviewed herein lend support to the notion that the endocannabinoid signalling system plays a key modulation role in the activities subserved by the hippocampus, which is directly or indirectly affected in epilepsy patients.
Conclusion:
The notion is supported by a variety of anatomical, electrophysiological, biochemical and pharmacological findings. These data suggest the need for developing novel treatments using compounds that selectively target individual elements of the endocannabinoid signalling system.
